Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 6Phase 3 3Phase 1/2 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 5Pancreatic Neoplasms 2Glioblastoma 2Breast Neoplasms 2Sarcoma 1Recurrence 1Prostatic Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

X-Rays 2Platinum 2Magnetic Resonance Spectroscopy 2Hyperthermic Intraperitoneal Chemotherapy 2Drug Therapy 2Cytoreduction Surgical Procedures 2Cisplatin 2Aspirin 21,2-diaminocyclohexaneplatinum II citrate 2talazoparib 1sodium thiosulfate 1propranolol CR 1pembrolizumab 1olaparib 1epacadostat 1adavosertib 1Taxes 1Specimen Handling 1Propranolol 1Paclitaxel 1Ketorolac Tromethamine 1Ketorolac 1Fluoresceins 1Fluorescein 1Doxorubicin 1Carboplatin 1Auranofin 14-(3-fluoropropyl)glutamic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Fallopian Tube Neoplasms × olaparib × Clear all
NCT03943173 2026-02-25

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
15 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡